Trulicity Cost in Pennsylvania 2026: Cash Price, Insurance, Medicaid and Legal Alternatives

What Does Trulicity Actually Cost in Pennsylvania in 2026?

The manufacturer list price for Trulicity is $931 per month in Pennsylvania, identical to the national Eli Lilly wholesale acquisition cost. That figure covers four once-weekly pens (0.75 mg or 1.5 mg). Very few cash-pay patients in Pennsylvania pay that full amount because manufacturer assistance programs, pharmacy benefit managers, and insurance contracts all push the real out-of-pocket number down significantly. The FDA-approved label for Trulicity confirms the drug's subcutaneous delivery mechanism and dosing schedule, which has remained unchanged since initial approval in 2014 [1].

Pennsylvania retail pharmacies price Trulicity close to the list price when no insurance or discount card is applied, averaging around $931 per month on a cash basis in 2026. GoodRx and similar discount aggregators sometimes show prices 10 to 20 percent lower at specific chains, but those discounts are not stackable with insurance and do not count toward your deductible. Patients should confirm pricing at their specific pharmacy before assuming a discount card figure will hold.

Eli Lilly publishes a Trulicity Savings Card through its LillyInsulin and Lilly Cares programs. Commercially insured patients in Pennsylvania who meet eligibility criteria may pay as little as $25 per monthly supply. Uninsured patients with household income below 400 percent of the federal poverty level may qualify for Lilly Cares Foundation assistance, which can cover the full cost [2]. The FDA's drug-pricing transparency portal lists Trulicity among the branded GLP-1 receptor agonists subject to the Inflation Reduction Act negotiations, though dulaglutide's negotiated Medicare price does not take effect until after 2025 [1].

Dulaglutide's mechanism, once-weekly GLP-1 receptor agonism, is well-documented. The drug's receptor binding kinetics and its effect on fasting and postprandial glucose are reviewed in the published pharmacology literature at PubMed [3]. Understanding that mechanism matters for cost conversations because biosimilar and compounded alternatives work through the same pathway, which is directly relevant to the legal alternative section below.

Does Pennsylvania Medicaid Cover Trulicity?

Pennsylvania Medicaid covers Trulicity for type 2 diabetes with prior authorization. Coverage is available through Pennsylvania's Medical Assistance program, and the drug appears on the Pennsylvania Department of Human Services (PA DHS) preferred drug list for the GLP-1 receptor agonist class [4]. Prior authorization criteria typically require a confirmed type 2 diabetes diagnosis, a hemoglobin A1c above a threshold specified by managed care organizations (commonly 7.5 percent or higher), and documentation that metformin or another first-line agent was tried first.

Pennsylvania Medicaid is administered through HealthChoices managed care plans, including UPMC Health Plan, Geisinger Health Plan, Aetna Better Health, and Keystone First, among others. Each plan may have slightly different step-therapy requirements. The American Diabetes Association's 2024 Standards of Care in Diabetes describe GLP-1 receptor agonists as preferred agents in patients with established cardiovascular disease, chronic kidney disease, or high cardiovascular risk, language that can support prior authorization appeals [5]. Quoting directly from those standards: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended" [5].

Dual-eligible patients enrolled in both Medicare and Pennsylvania Medicaid may access Trulicity through their Medicare Part D plan. Part D coverage varies by plan formulary tier, and out-of-pocket costs under the redesigned 2025 Part D benefit are capped at $2,000 annually for enrollees who reach catastrophic coverage [6]. This cap is meaningful for patients who previously spent thousands per year on Trulicity under the old structure.

Is Compounded Dulaglutide Legal in Pennsylvania?

Compounded dulaglutide from licensed 503A compounding pharmacies is currently legal in Pennsylvania. The distinction that matters legally is between 503A compounding pharmacies, which compound for individual patients with a valid prescription, and 503B outsourcing facilities, which produce larger batches [7]. Pennsylvania's State Board of Pharmacy licenses 503A pharmacies and they may compound dulaglutide when a prescriber determines a compounded product is medically necessary for a specific patient.

The FDA placed semaglutide on the shortage list in prior years, opening a window for 503B bulk compounding that does not apply to dulaglutide. Dulaglutide has not appeared on the FDA drug shortage database as of the publication date of this article [7]. That means 503B outsourcing facilities cannot legally produce bulk compounded dulaglutide for general distribution. Individual 503A pharmacies can still compound it with a valid prescription, provided they source active pharmaceutical ingredients from FDA-registered suppliers and comply with USP standards.

Patients considering compounded dulaglutide in Pennsylvania should verify three things. First, confirm the pharmacy holds an active Pennsylvania 503A license. Second, confirm the API source is FDA-registered. Third, confirm the prescriber has documented medical necessity in the chart. The FDA has issued several guidance documents on compounded GLP-1 products, and the agency's position on quality standards for compounded peptides is available on its drug compounding page [7]. A 2023 FDA guidance update reinforced that compounded products must meet the same sterility and potency standards as commercially manufactured injectables, regardless of compound class [7].

Cost of compounded dulaglutide varies widely by pharmacy. Some Pennsylvania 503A pharmacies have charged as little as $150 to $300 per month, though pricing is not regulated and fluctuates with API supply chains. Compounded versions are not bioequivalent substitutes in the regulatory sense; they are patient-specific preparations.

The REWIND Trial: Why Cardiovascular Benefit Matters for Coverage Decisions

Dulaglutide's coverage under Pennsylvania Medicaid and commercial plans for patients with cardiovascular disease rests partly on the REWIND trial, published in The Lancet in 2019. REWIND enrolled 9,901 adults with type 2 diabetes, of whom 69 percent had prior cardiovascular disease or multiple cardiovascular risk factors. Participants were randomized to dulaglutide 1.5 mg once weekly or placebo and followed for a median of 5.4 years [8].

The primary endpoint, a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (MACE), occurred in 12.0 percent of the dulaglutide group versus 13.4 percent of the placebo group. That translates to a 12 percent relative risk reduction (HR 0.88; 95% CI 0.79 to 0.99; P<0.026) [8]. The absolute risk reduction was 1.4 percentage points over 5.4 years, a number that contextualizes the magnitude of benefit for shared decision-making.

The Lancet authors noted that REWIND was distinctive because it included patients with fewer prior cardiovascular events than trials like LEADER (liraglutide) or SUSTAIN-6 (semaglutide), suggesting cardiovascular protection may extend to lower-risk type 2 diabetes populations [8]. This broader population finding supports PA Medicaid prior authorization requests for patients who do not yet have established cardiovascular disease but carry multiple risk factors.

A 2021 meta-analysis published in JAMA Cardiology pooled data across GLP-1 receptor agonist cardiovascular outcome trials and confirmed a class-level 14 percent reduction in MACE (RR 0.86; 95% CI 0.80 to 0.93) [9]. Dulaglutide's individual trial result aligns with that class estimate and strengthens the clinical rationale for coverage.

Which Insurance Plans Cover Trulicity in Pennsylvania?

Most major commercial insurers operating in Pennsylvania cover Trulicity, though tier placement and step-therapy requirements vary. BlueCross BlueShield of Pennsylvania, Highmark, Aetna, Cigna, UnitedHealthcare, and Independence Blue Cross all list Trulicity on their 2026 formularies, though specific tier assignments change annually at plan renewal [10]. Tier 3 specialty placement is the most common, which typically means a copay of $50 to $150 per fill after deductible, depending on plan design.

Step-therapy protocols at most Pennsylvania commercial plans require a trial of metformin and sometimes one other oral agent before Trulicity is approved. The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend GLP-1 receptor agonists as preferred add-on therapy when A1c is above goal despite metformin in patients with atherosclerotic cardiovascular disease, and that guideline text can anchor an appeal letter [11]. Quoting from the AACE Comprehensive Diabetes Management Algorithm: "GLP-1 RA therapy is preferred for patients with T2D and ASCVD, CKD, or high risk of ASCVD" [11].

Employer-sponsored self-insured plans in Pennsylvania are regulated under ERISA, not Pennsylvania state insurance law, so the Pennsylvania Insurance Department's mandates do not automatically apply to those plans. Patients on self-insured plans should contact their plan's pharmacy benefit manager directly to request formulary exception documentation.

Prescription drug monitoring programs in Pennsylvania do not restrict GLP-1 access, as dulaglutide is not a controlled substance. No Pennsylvania prescribing limit applies beyond what individual plans impose through utilization management.

How the Eli Lilly Savings Card Works in Pennsylvania

Eli Lilly operates two assistance pathways relevant to Pennsylvania patients: the Trulicity Savings Card for commercially insured patients and the Lilly Cares Foundation for uninsured or underinsured patients. The Savings Card program allows eligible commercially insured patients to pay as little as $25 per monthly prescription, with Lilly covering up to a defined amount of the remaining balance [2].

Pennsylvania patients can activate the savings card through Lilly's website or through their prescriber's office. The card is not valid for patients whose primary insurance is a government program, including Medicare Part D, Pennsylvania Medicaid, CHIP, or Tricare. Patients with commercial employer coverage as primary insurance are generally eligible, even if they also have Medicaid secondary coverage.

The Lilly Cares Foundation has different income eligibility thresholds and provides Trulicity at no cost to qualifying patients. Applications go through the Lilly Cares website and require documentation of income, insurance status, and a valid prescription. Processing time is typically two to four weeks for initial applications [2]. Patients in financial hardship should also ask their prescriber about the LillyInsulin.com portal, which consolidates multiple Lilly patient assistance programs into one application.

Pennsylvania also operates PACE and PACENET, state pharmaceutical assistance programs for older adults. PACE covers Trulicity for qualifying low-income Pennsylvania residents age 65 and older with income below $14,500 annually for singles or $17,700 for couples. PACENET thresholds are higher, reaching $27,500 for singles and $35,200 for couples [12]. Both programs charge a copay structure rather than full price and are administered through the Pennsylvania Department of Aging.

Can a Pennsylvania Telehealth Visit Generate a Trulicity Prescription?

Telehealth prescribing of Trulicity is permitted in Pennsylvania. Pennsylvania enacted permanent telehealth prescribing authority through Act 42 of 2021, which allows licensed physicians, physician assistants, certified registered nurse practitioners, and other eligible prescribers to prescribe Schedule II and non-scheduled medications, including Trulicity, via synchronous audio-visual telehealth encounters [13].

A valid prescriber-patient relationship must be established before prescribing. Pennsylvania does not permit prescribing based on asynchronous questionnaires alone for new patients; a real-time video or telephone encounter is required [13]. Prescribers licensed in Pennsylvania may prescribe to Pennsylvania residents regardless of where the prescriber is physically located during the encounter, provided the prescriber holds an active PA license.

Telehealth platforms operating in Pennsylvania, including HealthRX, can initiate Trulicity prescriptions during an initial visit if clinically appropriate. Follow-up visits to monitor A1c response, gastrointestinal tolerability, and injection technique can also occur via telehealth. The Centers for Medicare and Medicaid Services' telehealth policy pages confirm that Medicare beneficiaries in Pennsylvania can receive telehealth diabetes management services billed to Part B [14].

Dulaglutide requires refrigeration between 36 and 46 degrees Fahrenheit and can be stored at room temperature below 86 degrees Fahrenheit for up to 14 days. Pharmacies in Pennsylvania can ship Trulicity with cold-pack packaging, making mail-order delivery compatible with telehealth prescribing workflows.

What Is the Cheapest Way to Get Trulicity in Pennsylvania?

The lowest realistic out-of-pocket cost pathway depends on a patient's insurance status. For commercially insured Pennsylvania patients, combining plan coverage with the Lilly Savings Card to reach the $25 copay target is the most direct route. For uninsured patients with income below 400 percent of the federal poverty level, the Lilly Cares Foundation program may provide Trulicity at no charge [2].

Pennsylvania Medicaid enrollees with prior authorization approval pay no out-of-pocket cost for Trulicity fills at participating pharmacies, as Pennsylvania Medicaid does not charge copays for preferred medications in most HealthChoices plans [4]. For Medicare Part D enrollees, the 2025 redesign caps total out-of-pocket at $2,000, which helps patients who previously hit catastrophic coverage thresholds on Trulicity alone [6].

Compounded dulaglutide through a licensed Pennsylvania 503A pharmacy sits at a lower price point than brand-name Trulicity for patients who cannot access savings programs. Cash prices from 503A pharmacies range from roughly $150 to $300 per month as of early 2026, though patients should request a certificate of analysis confirming potency and sterility before use. The FDA's framework for evaluating compounded drug quality is published in its draft guidance on compounding from bulk substances [7].

GoodRx Gold and similar discount programs reduce the retail cash price at Pennsylvania chains. Walmart, CVS, Rite Aid, and Walgreens in Pennsylvania all accept GoodRx, and the discounted price at some locations has reached $800 to $850 per month, still well above compounded alternatives but below full list for patients who are ineligible for other programs.

Patients who have been stable on Trulicity for more than 12 months and whose A1c is at goal may discuss with their prescriber whether dose reduction from 1.5 mg to 0.75 mg is appropriate. The 0.75 mg pen carries the same list price as the 1.5 mg pen but may be clinically adequate for some patients, and a dose reduction does not itself reduce the monthly cost. It remains one prescription fill per month regardless of dose.

Monitoring, Side Effects, and Clinical Context Relevant to Pennsylvania Prescribers

Dulaglutide's most common adverse effects are gastrointestinal, including nausea, diarrhea, and vomiting, occurring in roughly 12 to 21 percent of patients at the 1.5 mg dose in the AWARD clinical trial program [15]. These effects are dose-dependent and typically resolve within four to eight weeks of initiating therapy. Renal function should be monitored in patients with pre-existing CKD, as GI fluid losses can worsen prerenal azotemia.

The FDA label carries a boxed warning for a risk of thyroid C-cell tumors based on rodent studies, though the clinical relevance in humans remains uncertain. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1].

A 2020 analysis published in Diabetes Care examined real-world persistence with once-weekly GLP-1 receptor agonists and found that dulaglutide had a 12-month persistence rate of approximately 55 percent compared with 47 percent for exenatide extended-release, suggesting the pen device design may support adherence in practice [16]. Pennsylvania prescribers counseling patients on injection technique can review the FDA-approved device instructions, which are included in the Trulicity prescribing information [1].

Baseline A1c, weight, blood pressure, and renal function should be documented before initiating therapy. Follow-up A1c testing at three months is standard practice consistent with American Diabetes Association guidance, which recommends A1c monitoring every three months when therapy is changed or when goals are not being met [5].